⌘+K

October 1, 2025Obstetrical & Gynecological Survey

Relacorilant and Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer (ROSELLA): An Open-label, Randomized, Controlled, Phase 3 Trial

View at Publisher

Ask AI

Bookmark

Share

Key Points

The trial shows promising results for relacorilant and nab-paclitaxel in treatment response among platinum-resistant ovarian cancer patients.
Approximately 70% of ovarian cancer patients exhibit resistance to platinum-based chemotherapy, indicating a need for alternative therapies.
This phase 3 trial evaluates new treatment options for ovarian cancer patients unresponsive to traditional platinum therapies.
Effective management of platinum-resistant ovarian cancer could significantly improve patient outcomes and survival rates.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Open-label phase 3 trial of relacorilant and nab-paclitaxel shows promise for platinum-resistant ovarian cancer, suggesting new treatment avenues.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Olawaiye et al. (2025) studied this question.

synapsesocial.com/papers/68e6679587ecc93a24d17752 https://doi.org/10.1097/01.ogx.0001169628.43305.4c

View at Publisher

Ask AI

Bookmark

Share